



# Takeda's Position on Public Policy Engagement

---

## Summary

- Public policy decisions at the national and global level have a major impact on how Takeda fulfils its purpose of bringing better health to people and a brighter future to the world.
- As part of delivering on our commitment to patients, people, and the planet, public policy engagement is an important activity, and we believe it is appropriate for companies when conducted in a legal and transparent manner.
- Advocacy means a range of activities to raise awareness of issues and influence policy. Takeda engages in public policy through advocacy with the overall objective of providing health benefits that are valued by patients and society.
- Our advocacy includes sharing scientific knowledge and fact-based information, lobbying in support or opposition to specific legislation, making political contributions, and participating in trade organizations.
- In line with its corporate values and in accordance with legal obligations, Takeda discloses financials related to policy influence at least annually.

## Background

Our purpose at Takeda is bringing better health to people and a brighter future to the world. Policymakers are critical partners in achieving this, because governments have a critical role in providing high quality, affordable healthcare for their citizens. Government transfers account for

nearly half of all health care spending in high income countries<sup>1</sup>. In addition, government policies, legislation and regulations impact the entire healthcare and innovation ecosystem. In a highly regulated pharmaceutical industry, public policy has the potential to affect our ability to deliver life-transforming treatments to the patients we serve.

## Takeda's Perspective

Given the role policymakers have in the delivery of treatment and improving patient outcomes, we believe that constructive public policy engagement, conducted in a legal and transparent manner, is fundamental to achieving our purpose and goal of providing health benefits that are valued by patients and society.

Takeda engages in public policy issues through advocacy including lobbying activities, political contributions and membership in trade organizations, all with the objective of fostering a policy environment conducive to investing in innovation, expanding patient access and contributing to the general betterment of the healthcare system. We share scientific knowledge and fact-based information with policymakers and regulatory authorities to inform public debate. As with all we do, our public policy engagement is guided by our values of Takeda-ism, which incorporate integrity, fairness, honesty and perseverance, and are brought to life through actions based on Patient-Trust-Reputation-Business, in that order.

### Corporate Lobbying Expenditures

Takeda lobbies directly through Takeda government and public affairs employees or indirectly through qualified third-party intermediaries, in accordance with applicable registration and disclosure laws. Please see our latest disclosure of spending on lobbying, interest representation or similar in [Appendix 1](#).

In the U.S., Takeda files quarterly lobbying reports that capture federal lobbying activity in the Congress and with any federal agencies. Takeda's reports can be found on the [Congressional lobby disclosure website](#). In the European Union, Takeda files annual reports on its spending on activities to influence the EU policy and decision-making process. Takeda's reports can be found on the [EU Transparency Register](#).

---

<sup>1</sup> Global expenditure on health: public spending on the rise? Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. (p.19).

## **Political Contributions**

Takeda makes political contributions transparently and in compliance with laws and regulations as part of engaging in public policy discussions. Takeda is committed to supporting candidates of any political party using fair and objective criteria in the selection of candidates – including those who support public policies that contribute to our goal of providing health benefits that are valued by patients and society. Please see our latest disclosure of spending on political contributions in [Appendix 1](#).

In the U.S., political contributions are made from two different sources: Takeda’s Political Action Committee (TakPAC) and from corporate funds where legally allowed. TakPAC is a separate, segregated fund registered with the Federal Election Commission and connected to Takeda Pharmaceuticals America, Inc. as a Lobbyist/Registrant PAC. The purpose of TakPAC is to provide monetary contributions and other support to candidates for federal, state, and local offices. Employee participation in TakPAC is completely voluntary, all contribution guidelines are only suggestions, and employees are free to contribute more or less than the guidelines or nothing at all. Takeda will neither favor nor disadvantage any employee due to the amount of their contribution or decision not to contribute. TakPAC activity reports are filed monthly with additional reporting requirements during an election year. The list of all PAC contributions is included in the [TakPAC Annual Report](#).

Separate from corporate contributions, Takeda employees may make political contributions and carry out political activities in their personal capacity, but they are prohibited from any political involvement that would compromise their role and responsibilities at Takeda.

## **Trade Associations**

Industry associations provide Takeda with an important opportunity to communicate our sector’s commitment to patients and other stakeholders while contributing our perspectives and experience in support of good policy outcomes. Takeda is a member of national and international trade and industry associations that represent the pharmaceutical industry and aim to bring about consensus on broad policy issues. Our participation as a member of these associations comes with the understanding that we may not always agree with the positions of the larger organization or other members, and that we are committed to voicing our concerns as appropriate through our colleagues who serve on the boards and committees of these groups.

Please see our latest disclosure of spending on trade association memberships in [Appendix 1](#). We also disclose a list of current trade association memberships in the U.S., Europe, and Japan where annual dues are more than ¥5 million in [Appendix 2](#).

## Conclusion

Policymakers are critical partners in fulfilling our purpose as a biopharmaceutical company because government policies, regulations, and legislation impact the entire healthcare and innovation ecosystem. We believe public policy engagement is an important activity, and it is appropriate for companies when conducted in a legal and transparent manner. Takeda engages in public policy issues through responsible lobbying activities, political contributions and membership in trade organizations, with the objective of improving health outcomes for society. In line with its corporate values and in accordance with legal obligations, Takeda discloses financials related to lobbying, political contributions and trade association memberships at least annually.

## About Takeda Pharmaceutical Company Limited

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare disease, plasma-derived therapies, neuroscience, oncology and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline.

**September 2023**

## Appendix 1

### Takeda Financial Year 2022<sup>1</sup> Spending Related to Public Policy in the United States of America, European Union, and Japan<sup>2</sup> (units: millions JPY)

	FY2021	FY2022
<b>Corporate Lobbying Expenditures<sup>3</sup></b>	<b>659.8</b>	<b>855.3</b>
<b>Political Contributions</b>	<b>36.6</b>	<b>47.3</b>
<b>Trade Association Memberships<sup>4</sup></b>	<b>3,782.9</b>	<b>3,858.1</b>

<sup>1</sup> The period 1 April 2022 – 31 March 2023

<sup>2</sup> The United States of America, European Union, and Japan accounted for 85.8% of our revenues in 2022. Conversion of currency and % of revenues has been calculated as per Takeda's FY2022 Q4 Earnings Announcement (1 USD = 135 JPY, 1 EUR = 141 JPY).

<sup>3</sup> FY2021 data includes a 50% deduction for Brussels office overheads applied to Takeda's disclosure in the EU Transparency Register; this deduction was not applied in FY2022.

<sup>4</sup> For the European Union, spend on pan-European trade associations only.

Last updated: September 2023

## Appendix 2

### Takeda FY2022<sup>1</sup> Trade Association Memberships

Below is a list of trade associations in the United States of America, Europe<sup>2</sup>, and Japan to which Takeda makes annual membership payments over 5 million yen.

#### USA

- Biotechnology Innovation Organization (BIO)
- California Life Sciences Association (CLSA)
- Massachusetts Biotechnology Council (MassBio)
- National Council for Behavioral Health - Partnership for Part D Coalition
- National Health Council
- National Pharmaceutical Council (NPC)
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- Plasma Protein Therapeutics Association (PPTA)
- The Medical Alley Association

#### Europe

- EuropaBio
- European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
- Vaccines Europe

#### Japan

- Japan Pharmaceutical Manufacturers Association (JPMA)
- Kansai Pharmaceutical Industries Association
- Japan Association of Vaccine Industries (JAVI)
- Japan Blood Products Association

<sup>1</sup> The period 1 April 2022 – 31 March 2023

<sup>2</sup> Memberships of pan-European trade associations only

Last updated: September 2023